Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

By Rene Pretorius

June 30, 2025

Summary
The U.S. Department of Health and Human Services (HHS) announced a collaboration with major insurers to streamline prior authorization reforms for Medicare Advantage, Medicaid, and commercial plans. The initiative targets standardized electronic submissions by 2027. It also aims to reduce prior authorization requirements by 2026. The goal is to accelerate care decisions and minimize delays through real-time approvals and clinician-reviewed denials. Participating insurers, covering 257 million Americans, pledged to honor existing authorizations during coverage transitions. They also committed to improving communication during appeals.

Key Insights
The reforms prioritize six core commitments. These include electronic standardization via FHIR-based APIs and reduced prior authorization volumes by 2026. Other commitments are continuity of care during plan transitions, improved transparency, real-time approvals by 2027, and clinician oversight of denials. This effort aligns with CMS’s Interoperability and Prior Authorization rule. It addresses systemic barriers that delay care despite medical necessity. Notably, bipartisan congressional support underscores the urgency of these reforms. Physicians continue to cite prior authorization as a major obstacle to timely treatment.

Background Context
Prior authorization has long been criticized for creating administrative burdens and care delays. A reported 94% of physicians say it leads to treatment delays. Additionally, 80% note patient abandonment of necessary care. The initiative builds on CMS’s existing regulatory framework. It seeks to reduce redundancy and leverage interoperability standards for seamless electronic submissions. Reputable sources, such as the American Medical Association, have documented the negative impacts of prior authorization.

Implications for HEOR
The prior authorization reforms could significantly reduce administrative costs for providers and payors. Standardizing electronic submissions and minimizing redundant requests may help. Faster approvals could enhance health outcomes by reducing delays in critical diagnostics and procedures. Real-time responses and FHIR standardization may improve data interoperability. This could enable more robust cost-effectiveness analyses and reduce care access disparities. However, success depends on insurer compliance and CMS’s enforcement capacity.

In the long term, these changes may lead to cost savings from reduced administrative overhead. They could also improve resource allocation in high-value care areas. Additionally, they may support HEOR research by providing standardized datasets. While the initiative addresses inefficiencies, challenges remain in tackling systemic inequities. For more information, refer to the detailed source here.

Reference url

Recent Posts

PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic Infrastructure and Care

By HEOR Staff Writer

September 30, 2025

Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $500 billion in new U.S. infrastructure spending. I...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025

By HEOR Staff Writer

September 29, 2025

Are you searching for effective Sanofi insulin savings options to manage diabetes medication costs in 2025? The Sanofi Patient Connection Savings Registration program offers an efficient pathway for eligible patients to save on key insulin products—helping reduce out-of-pocket expenses and promot...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals

By Rene Pretorius

September 26, 2025

In the interconnected landscape of pharmaceutical regulation and innovation, the Track One patent strategy in pharmaceuticals serves as an important component that influences the timing of mar...